• Explore /
  • Poster
  • / Study protocol of an open-label, single-arm, phase II trial investigating the efficacy and safety of trifluridine/tipiracil combined with irinotecan as a second-line therapy in patients with cholangiocarcinoma (TRITICC).

Study protocol of an open-label, single-arm, phase II trial investigating the efficacy and safety of trifluridine/tipiracil combined with irinotecan as a second-line therapy in patients with cholangiocarcinoma (TRITICC).

Abstract Video & Slides Poster

Authors

null

Linde Kehmann

Charité University Medicine Berlin, Berlin, Germany

Linde Kehmann , Marie Berres , Maria A Gonzalez-Carmona , Dominik Paul Modest , Raphael Mohr , Alexander Wree , Marino Venerito , Christian Strassburg , Verena Keitel , Christian Trautwein , Tom Luedde , Christoph Roderburg

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT04059562

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS4176)

DOI

10.1200/JCO.2022.40.16_suppl.TPS4176

Abstract #

TPS4176

Poster Bd #

153b

Abstract Disclosures

Similar Posters

First Author: Sherise C. Rogers

First Author: Sherise C. Rogers

First Author: Sherise C. Rogers

First Author: Zhichao Jiang